Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for NSCLC at High Risk of Recurrence Following Resection and Chemotherapy
Click here to view original post